6-azauridine for the Treatment of SARS-CoV-2
Combined with fast diagnostic tools to recognize 2019-nCoA infection, antivirals may provide a more appropriate therapy. As the largest class of small molecule-based antivirals for chemotherapy of virus infections, nucleoside analogs are featured with high antiviral potency and favorable pharmacokinetics parameters. A nucleoside analog, 6-azauridine, has been demonstrated to be a broad antiviral agent, and therefore, this compound can be potentially used in the treatment of 2019-nCoA. As a long-term expert in the field of immunology, Creative Biolabs offers high-quality validation service of 6-azauridine for the treatment of SARS-CoV-2.
Nucleoside analogs are synthetic, chemically modified nucleosides. They mimic their endogenous nucleosides and block viral replication by impairing nucleoside synthesis or by inhibition of viral enzymes involved in nucleoside metabolism. Nucleoside analog inhibitors have figured prominently in the search for effective antiviral agents. They are known for their inhibition of several types of viruses, including hepacivirus, ﬂavivirus, West Nile virus, human immunodeficiency virus (HIV), and severe acute respiratory syndrome (SARS-CoV).
6-azauridine is a uridine analogue with a histidine-like N-3 pKa. It is used as an antineoplastic antimetabolite as it interferes with pyrimidine biosynthesis, thereby preventing the formation of cellular nucleic acids. The antiviral effect of 6-azauridine has previously been documented for several virus types, including coronaviruses, ﬂaviviruses and West Nile virus. This compound may thus act as a broad antiviral agent. 6-azauridine has already been used in patients in the treatment of other diseases. It should be further considered for use, either alone or in combination, for the treatment of 2019-nCoA infection. Therefore, its potential usefulness in the treatment of 2019-nCoA infections should be further evaluated.
Fig.1 Inhibition of HCoV-NL63 with 6-azauridine. (A) Structure of 6-azauridine. (B) CPE reduction mediated by 6-azauridine. (C) Decrease in HCoV-NL63 virus yield after treatment with 6-azauridine and cell viability assay. (Pyrc, 2006)
The lack of an effective vaccine or drug motivates us to design and evaluate therapeutic agents that could inhibit 2019-nCoA infection and thus provide a potential therapy for the treatment of 2019-nCoA. Based on existing research, 6-azauridine may be used in a mono- or multi-drug therapy setting, thereby inhibiting 2019-nCoA infection. Equipped with world-leading technology platforms and professional scientific staff, Creative Biolabs offers high-quality custom validation service of 6-azauridine for the treatment of SARS-CoV-2 to meet even the most specific requirements.
Long-term devoted to the development of antiviral drug, Creative Biolabs is pleased to use our extensive experience and advanced platform to offer the best custom service for the treatment of SARS-CoV-2 to assist our customers’ research and project development. For more detailed information, please feel free to contact us or directly send us an inquiry.
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.